A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes

Name: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes
Creator: Vivli
Published: 2025-12-08 23:14:34
License: 暂无描述

DataCite Commons2025-12-08 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00002460/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.

提供机构：

Vivli

创建时间：

2018-10-27